Skip to main content
Bonnie Howell

Bonnie Howell

Associate Vice President, Pharmacology, Global HIV Cure Lead, Merck & Co., Inc.
United States

Bonnie Howell joined Merck & Co, Inc., in 2003 and contributed early on to Merck’s oncology drug discovery and RNA therapeutics efforts. In 2013, she moved to Infectious Disease and Vaccine Discovery, where she served as Executive Director of Merck’s antiviral and antibacterial drug and vaccine discovery and development. In this role, she has been responsible for advancing programmes against HIV, coronaviruses, respiratory viruses, Ebola and bacterial pathogens.

She has also served as co-chair of Merck’s global technology team of clinical investigators and research scientists for biomarker implementation and co-chair of a global committee on immune monitoring. Bonnie serves on Merck’s Global Innovation team focused on Global digital and analytical technologies. She leads the company’s efforts in HIV cure, which span corporate and academic partnerships aimed at HIV eradication.

The IAS promotes the use of non-stigmatizing, people-first language. The translations are all automated in the interest of making our content as widely accessible as possible. Regretfully, they may not always adhere to the people-first language of the original version.